Actively Recruiting

Age: 18Years +
All Genders
Healthy Volunteers
NCT06878027

Analysis of Urinary Methylation Patterns Via Liquid Biopsy as an Early Diagnosis Tool

Led by Regina Elena Cancer Institute · Updated on 2025-03-14

100

Participants Needed

1

Research Sites

78 weeks

Total Duration

On this page

Sponsors

R

Regina Elena Cancer Institute

Lead Sponsor

A

Azienda Ospedaliera Santa Maria Degli Angeli

Collaborating Sponsor

AI-Summary

What this Trial Is About

Multicenter, observational, prospective, biological pilot study on liquid biopsy, aimed at investigating methylation profiles in relation to the early diagnosis of bladder cancer, to validate the potential of commercially available tests (e.g. BladderCARE, Bladder EpiCheck), to apply and validate tests based on targeted multi-marker or genome wide analyzes via NGS and to identify methylation profiles as a tool to infer clinical outcome.

CONDITIONS

Official Title

Analysis of Urinary Methylation Patterns Via Liquid Biopsy as an Early Diagnosis Tool

Who Can Participate

Age: 18Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Proven diagnosis of bladder cancer (infiltrating muscle or non-infiltrating muscle)
  • Performance status 0 or 1
  • Ability to follow study procedures
  • Written consent for participation and data processing
  • Age 18 years or older (healthy subjects)
  • Ability to follow study procedures (healthy subjects)
  • Written consent for participation and data processing (healthy subjects)
Not Eligible

You will not qualify if you...

  • Presence of metastatic bladder cancer (patient group)
  • Lack of autonomy in following study procedures (patient group)
  • Previous or current history of bladder cancer (healthy subjects)
  • Suspicion of tumor pathologies (healthy subjects)
  • Ongoing or previous systemic oncological treatments (healthy subjects)
  • Presence of inflammatory or autoimmune diseases that may affect methylation profiles (healthy subjects)
  • Use of pharmacological or other treatments that could alter study analysis results (healthy subjects)
  • Lack of autonomy in following study procedures (healthy subjects)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

IRCCS National Cancer Institute "Regina Elena"

Rome, Italy, 00144

Actively Recruiting

Loading map...

Research Team

G

Giuseppe Simone, Medical Doctor

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here